Skip to main content
. Author manuscript; available in PMC: 2011 Jun 13.
Published in final edited form as: Cancer Causes Control. 2011 Feb 13;22(4):611–621. doi: 10.1007/s10552-011-9734-7

Table 3.

Mean post-menarche hormone and SHBG concentrations in DISC girls according to (a) birth weight, (b) birth weight, adjusted for years since menarche

n samples
n individuals
(max samples per individual)		 Lower birth weight ≤2,892 g Mean (95% CI) Average birth weight 2,920–3,884 g Mean (95% CI) Higher birth weight ≥3,912 g Mean (95% CI) p value
(a)
Combined luteal and follicular phase
 Androstenedione, ng/dl‡ 346 139.17 (124.70, 155.31) 126.65 (119.41, 134.33) 122.90 (108.30, 139.49) 0.211
205 0.082
3
 Testosterone, ng/dl‡ 343 31.20 (27.01, 36.05) 28.25 (26.19, 30.47) 27.58 (23.43, 32.46) 0.381
205 0.202
3
 DHEAS, lg/dl‡ 347 125.19 (107.07, 146.35)a 104.06 (96.13, 112.65)a 103.60 (86.7, 123.80) 0.081
205 0.172
3
 SHBG, nmol/dl‡ 348 61.76 (52.63, 72.49) 62.82 (57.95, 68.12) 66.84 (55.72, 80.17) 0.781
205 0.422
3
Luteal phase
 Estradiol, ng/dl‡ 162 10.13 (7.56, 13.38) 10.05 (8.59, 11.77) 10.66 (7.64, 14.88) 0.951
127 0.722
3
 Non-SHBG-bound estradiol, ng/dl‡ 162 5.10 (3.87, 6.70) 5.06 (4.36, 5.87) 5.52 (4.04, 7.55) 0.811
127 0.632
3
 Estrone, ng/dl‡ 162 5.50 (4.37, 6.94) 5.22 (4.62, 5.91) 5.68 (4.37, 7.38) 0.791
127 0.922
3
 Estrone sulfate, ng/dl‡ 165 130.86 (96.15, 178.11) 137.04 (116.37, 161.40) 157.51 (112.98, 219.60) 0.681
127 0.522
3
 Progesterone, ng/dl‡ 160 117.79 (66.74, 207.91) 107.62 (79.06, 146.50) 83.70 (44.02, 159.14) 0.701
127 0.622
3
Follicular phase
 Estradiol, ng/dl‡ 179 4.48 (3.51, 5.72) 4.33 (3.89, 4.81) 4.94 (3.59, 6.79) 0.761
141 0.592
3
 Non-SHBG-bound estradiol, ng/dl‡ 179 2.45 (1.90, 3.16) 2.17 (1.88, 2.51) 0.30 (1.66, 3.20) 0.641
141 0.222
3
 Estrone, ng/dl‡ 179 3.86 (3.28, 4.54) 3.45 (3.14, 3.78) 3.80 (3.09, 4.67) 0.311
141 0.282
3
 Estrone sulfate, ng/dl‡ 180 89.97 (70.58, 114.69) 80.71 (70.02, 93.05) 74.91 (54.78, 102.42) 0.591
141 0.372
3
 Progesterone, ng/dl† 175 31.26 (21.37, 45.72) 29.99 (23.98, 37.49) 29.41 (17.81, 48.56) 0.971
141 0.662
3
(b)
Combined luteal and follicular phase
 Androstenedione, ng/dl‡ 346 138.30 (124.05, 154.18) 128.23 (120.88, 136.02) 126.49 (111.39, 143.64) 0.401
205 0.162
3
 Testosterone, ng/dl‡ 343 31.97 (27.88, 36.66) 29.58 (27.81, 31.47) 29.15 (24.81, 34.25) 0.381
205 0.372
3
 DHEAS, lg/dl‡ 347 124.21 (106.40, 145.01) 106.03 (97.89, 114.85) 108.14 (90.38, 129.39) 0.171
205 0.312
3
 SHBG, nmol/dl‡ 348 61.65 (52.50, 72.38) 63.12 (58.13, 68.53) 67.56 (56.13, 81.32) 0.741
205 0.382
3
Luteal phase
 Estradiol, ng/dl‡ 162 10.04 (7.51, 13.43) 10.26 (8.76, 12.01) 11.03 (7.91, 15.37) 0.901
127 0.552
3
 Non-SHBG-bound estradiol, ng/dl‡ 162 5.04 (3.83, 6.61) 5.14 (4.43, 5.96) 5.68 (4.15, 7.76) 0.82
127 0.482
3
 Estrone, ng/dl‡ 162 5.50 (4.37, 6.94) 5.22 (4.62, 5.91) 5.68 (4.37, 7.38) 0.791
127 0.922
3
 Estrone sulfate, ng/dl‡ 165 130.86 (96.15, 178.11) 137.04 (116.37, 161.40) 157.51 (112.98, 219.60) 0.681
127 0.522
3
 Progesterone, ng/dl‡ 160 117.79 (66.74, 207.91) 107.62 (79.06, 146.50) 83.70 (44.02, 159.14) 0.701
127 0.622
3
Follicular phase
 Estradiol, ng/dl‡ 179 4.14 (3.18, 5.39) 4.02 (3.47, 4.65) 4.65 (3.32, 6.52) 0.691
141 0.612
3
 Non-SHBG-bound estradiol, ng/dl‡ 179 2.45 (1.90, 3.16) 2.17 (1.88, 2.51) 2.30 (1.66, 3.20) 0.651
141 0.232
3
 Estrone, ng/dl‡ 179 3.86 (3.28, 4.54) 3.45 (3.14, 3.78) 3.80 (3.09, 4.67) 0.311
141 0.322
3
 Estrone sulfate, ng/dl‡ 180 89.97 (70.58, 114.69) 80.71 (70.02, 93.05) 74.91 (54.78, 102.42) 0.641
141 0.412
3
 Progesterone, ng/dl‡ 175 31.26 (21.37, 45.72) 29.99 (23.98, 37.49) 29.41 (17.81, 48.56) 0.981
141 0.862
3

SD standard deviation, CI confidence interval, SHBG sex hormone–binding globulin, DHEAS dehydroepiandrostenedione sulfate

a

Items in the same row marked with the same letter differ at p ≤ 0.05

1

p value for categorical birth weight;

2

p value for continuous birth weight

†

Geometric means and 95% CI adjusted for visit number, treatment group, and age; estrogens and progesterone adjusted for menstrual cycle day

‡

Geometric means and 95% CI adjusted for visit number, treatment group, age, years since menarche; estrogens and progesterone adjusted for menstrual cycle day